Other languages Perseus Proteomics Inc.

Equities

4882

JP3836800007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-05 am EDT			5-day change	1st Jan Change
470 ^JPY	-2.89%		+7.06%	-23.95%

Jun. 18	Perseus Proteomics' Interim Report for Phase I Clinical Trial of PPMX-T003 Accepted at 14th JSH International Symposium	MT
May. 10	Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	May. 10
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	Feb. 14
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	Feb. 02
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 13
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	23-10-20
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	23-10-10
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	23-09-27
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	23-09-22
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	23-08-29
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-08-14
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	23-05-28
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-05-12
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	23-04-25
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	23-03-27
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	23-03-15
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	23-02-13
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-13
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients	23-02-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Perseus Proteomics Inc.

Equities

4882

JP3836800007

Other languages

Filters